Navigation Links
Proteon Therapeutics Completes $12 Million Financing and Hires CFO
Date:9/6/2007

WALTHAM, Mass., Sept. 6 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases, recently completed a $12 million financing with its current investor syndicate. Proteon will use these funds to advance its first product candidate, PRT-201, into human clinical studies in both hemodialysis vascular access and peripheral arterial disease. Proteon's investors include TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners. Concurrent with the investment, Proteon also announced the addition of Dr. Hubert Birner of TVM Capital and Dr. Garheng Kong of Intersouth Partners to the Proteon Therapeutics Board of Directors.

Additionally, the Company also announced the expansion of its management team with the recent hiring of Mark J. Fitzpatrick as its Vice President and Chief Financial Officer. Mr. Fitzpatrick brings over 17 years of biotechnology industry experience to Proteon.

"This is an exciting time for Proteon Therapeutics as we advance our lead drug candidate, PRT-201, toward clinical studies, and strengthen the company from a financial and human capital standpoint," said Timothy Noyes, Proteon's president and CEO. "We continue to benefit from a strong partnership with our investors and the current financing is evidence of their belief in our science and our team. The outstanding quality of our people and technology are also instrumental in our ability to attract world class talent such as Hubert, Garheng and Mark. Hubert and Garheng are great additions to our Board, and Mark brings tremendous financial and business skills to Proteon."

"Intersouth Partners was pleased to join the other existing investors in providing additional financing to Proteon as it advances PRT-201 toward human clinical study," said Garheng Kong of Intersouth Partners. "I personally look forward to working more closely with the Company as a new member of its Board of Directors."

Mark J. Fitzpatrick brings to Proteon more than 17 years experience in the financial management of biotechnology companies, including as Chief Financial Officer of RenaMed Biologics, Inc. and Dynogen Pharmaceuticals, Inc., both privately held companies, as well as Diacrin, Inc., where he successfully completed its IPO. He also held financial management positions at Repligen Corporation and served on the professional staff of Arthur Andersen and Co.

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. The company is headquartered in Waltham, MA and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sonic Foundry completes $11.25M stock offer
3. Orion Energy completes $5M capital round
4. RedPrairie completes MARC acquisition
5. Metavante completes purchase of check processing firm
6. GE completes $1.2 billion acquisition
7. M & Is Metavante completes Brasfield Corp. acquisition
8. Metavante completes GHR Systems acquisition
9. Metavante completes TREEV acquisition
10. Johnson Controls completes sale of French unit
11. OpGen completes $5 million investment round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election ... Health Care Business Conference will bring together over 500 top healthcare leaders for a ... in transformation. The conference, organized by MBA students of the University of Pennsylvania’s Wharton ...
(Date:2/9/2016)... Cupertino, CA (PRWEB) , ... February 08, 2016 ... ... and multilingual testing services, announced today the launch of its revamped and ... range of scalable language service solutions, the redesigned website will better communicate how ...
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for ... Certification Qualification Course for Technicians via a two part webinar on July 30 and ... review of hardware, software, and camera setup/operations, aligns with the in-person member qualification course ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, ... immunotherapies for cancer, announced that its lead ... European Commission as an orphan medicinal product ... deadliest form of glioma, strikes approximately 25,000 ... EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):